AIM: The aim of this study was to evaluate the efficacy and safety of radial extracorporeal shock wave therapy (rESWT) in the treatment of spasticity in patients with cerebral palsy. METHODS:Fifteen patients with spastic cerebral palsy, 12 men and 3 women, aged 10-46 years (mean age 31). The 15 patients presented 40 spastic muscles that were divided in three groups using a computerized random-number generator. The first group, received rESWT in spastic muscle. The second group received rESWT in spastic muscle + rESWT in antagonist muscle. The third group received placebo. Range of motion and Ashworth Scale were performed. This study is a randomized, placebo-controlled clinical trial. The patients were treated in 3 sessions at intervals of one week. RESULTS: There are significant differences between groups treated with rESWT and group placebo. A significant decrease in the Ashworth Scale, an increase in the range of motion, were observed in all patients that were treated with rESWT. Positive results were maintained for at least 2 months after treatment. INTERPRETATION: The treatment with rESWT is more effective than placebo in decreasing spasticity of patients with CP.
RCT Entities:
AIM: The aim of this study was to evaluate the efficacy and safety of radial extracorporeal shock wave therapy (rESWT) in the treatment of spasticity in patients with cerebral palsy. METHODS: Fifteen patients with spastic cerebral palsy, 12 men and 3 women, aged 10-46 years (mean age 31). The 15 patients presented 40 spastic muscles that were divided in three groups using a computerized random-number generator. The first group, received rESWT in spastic muscle. The second group received rESWT in spastic muscle + rESWT in antagonist muscle. The third group received placebo. Range of motion and Ashworth Scale were performed. This study is a randomized, placebo-controlled clinical trial. The patients were treated in 3 sessions at intervals of one week. RESULTS: There are significant differences between groups treated with rESWT and group placebo. A significant decrease in the Ashworth Scale, an increase in the range of motion, were observed in all patients that were treated with rESWT. Positive results were maintained for at least 2 months after treatment. INTERPRETATION: The treatment with rESWT is more effective than placebo in decreasing spasticity of patients with CP.
Authors: Seung Won Moon; Jin Hoan Kim; Mi Jin Jung; Seungnam Son; Joong Hoon Lee; Heesuk Shin; Eun Shin Lee; Chul Ho Yoon; Min-Kyun Oh Journal: Ann Rehabil Med Date: 2013-08-26
Authors: Tiantian Wang; Lin Du; Ling Shan; Hanyu Dong; Junyan Feng; Maren C Kiessling; Nicholas B Angstman; Christoph Schmitz; Feiyong Jia Journal: Medicine (Baltimore) Date: 2016-05 Impact factor: 1.889
Authors: Laura Mori; Lucio Marinelli; Elisa Pelosin; Antonio Currà; Luigi Molfetta; Giovanni Abbruzzese; Carlo Trompetto Journal: Biomed Res Int Date: 2014-09-17 Impact factor: 3.411
Authors: Nikolaus B M Császár; Nicholas B Angstman; Stefan Milz; Christoph M Sprecher; Philippe Kobel; Mohamed Farhat; John P Furia; Christoph Schmitz Journal: PLoS One Date: 2015-10-28 Impact factor: 3.240
Authors: Christoph Schmitz; Nikolaus B M Császár; Stefan Milz; Matthias Schieker; Nicola Maffulli; Jan-Dirk Rompe; John P Furia Journal: Br Med Bull Date: 2015-11-18 Impact factor: 4.291